{
  "approved_at_utc": null,
  "subreddit": "investing",
  "selftext": "Moderna Inc. announced its Q2 results on Thursday before the bell. \n\n**Key Highlights:**\n\n* Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates.\n* Moderna  COVID-19 Vaccine mRNA-1273: Final blinded analysis of Phase 3 COVE  study shows 93% efficacy; Efficacy remains durable through six *months after second dose ​*\n* Moderna booster candidates demonstrate robust antibody responses to COVID-19 variants of concern in Phase 2\n* Dosing  started in Phase 1 studies for quadrivalent seasonal flu vaccine  candidate (mRNA-1010) and IL-2 mRNA program for autoimmune disorders  (mRNA-6231)\n* Moderna  has mRNA candidates in clinical development across five therapeutic  areas: infectious disease, cardiovascular, oncology, rare disease and  autoimmune disorders\n* **Q2 total revenue of $4.4 billion, net income of $2.8 billion and diluted earnings per share of $6.46**\n* Moderna  establishes new Charitable Foundation to promote public health,  healthcare and educational opportunities, particularly in underserved  populations\n\n[https://risingcandle.com/business/moderna-announces-q2-results-crushes-earnings/](https://risingcandle.com/business/moderna-announces-q2-results-crushes-earnings/)",
  "author_fullname": "t2_9arxbmts",
  "saved": false,
  "mod_reason_title": null,
  "gilded": 0,
  "clicked": false,
  "title": "Moderna announces Q2 results; crushes earnings",
  "link_flair_richtext": [],
  "subreddit_name_prefixed": "r/investing",
  "hidden": false,
  "pwls": 6,
  "link_flair_css_class": null,
  "downs": 0,
  "top_awarded_type": null,
  "hide_score": false,
  "name": "t3_oyh3y7",
  "quarantine": false,
  "link_flair_text_color": "dark",
  "upvote_ratio": 0.86,
  "author_flair_background_color": null,
  "subreddit_type": "public",
  "ups": 198,
  "total_awards_received": 0,
  "media_embed": {},
  "author_flair_template_id": null,
  "is_original_content": false,
  "user_reports": [],
  "secure_media": null,
  "is_reddit_media_domain": false,
  "is_meta": false,
  "category": null,
  "secure_media_embed": {},
  "link_flair_text": null,
  "can_mod_post": false,
  "score": 198,
  "approved_by": null,
  "is_created_from_ads_ui": false,
  "author_premium": false,
  "thumbnail": "",
  "edited": false,
  "author_flair_css_class": null,
  "author_flair_richtext": [],
  "gildings": {},
  "content_categories": null,
  "is_self": true,
  "mod_note": null,
  "created": 1628168647,
  "link_flair_type": "text",
  "wls": 6,
  "removed_by_category": null,
  "banned_by": null,
  "author_flair_type": "text",
  "domain": "self.investing",
  "allow_live_comments": true,
  "selftext_html": "<!-- SC_OFF --><div class=\"md\"><p>Moderna Inc. announced its Q2 results on Thursday before the bell. </p>\n\n<p><strong>Key Highlights:</strong></p>\n\n<ul>\n<li>Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates.</li>\n<li>Moderna  COVID-19 Vaccine mRNA-1273: Final blinded analysis of Phase 3 COVE  study shows 93% efficacy; Efficacy remains durable through six <em>months after second dose ​</em></li>\n<li>Moderna booster candidates demonstrate robust antibody responses to COVID-19 variants of concern in Phase 2</li>\n<li>Dosing  started in Phase 1 studies for quadrivalent seasonal flu vaccine  candidate (mRNA-1010) and IL-2 mRNA program for autoimmune disorders  (mRNA-6231)</li>\n<li>Moderna  has mRNA candidates in clinical development across five therapeutic  areas: infectious disease, cardiovascular, oncology, rare disease and  autoimmune disorders</li>\n<li><strong>Q2 total revenue of $4.4 billion, net income of $2.8 billion and diluted earnings per share of $6.46</strong></li>\n<li>Moderna  establishes new Charitable Foundation to promote public health,  healthcare and educational opportunities, particularly in underserved  populations</li>\n</ul>\n\n<p><a href=\"https://risingcandle.com/business/moderna-announces-q2-results-crushes-earnings/\">https://risingcandle.com/business/moderna-announces-q2-results-crushes-earnings/</a></p>\n</div><!-- SC_ON -->",
  "likes": null,
  "suggested_sort": null,
  "banned_at_utc": null,
  "view_count": null,
  "archived": false,
  "no_follow": false,
  "is_crosspostable": false,
  "pinned": false,
  "over_18": false,
  "awarders": [],
  "media_only": false,
  "can_gild": false,
  "spoiler": false,
  "locked": false,
  "author_flair_text": null,
  "treatment_tags": [],
  "visited": false,
  "removed_by": null,
  "num_reports": null,
  "distinguished": null,
  "subreddit_id": "t5_2qhhq",
  "author_is_blocked": false,
  "mod_reason_by": null,
  "removal_reason": null,
  "link_flair_background_color": "",
  "id": "oyh3y7",
  "is_robot_indexable": true,
  "report_reasons": null,
  "author": "lazywizard99",
  "discussion_type": null,
  "num_comments": 30,
  "send_replies": true,
  "whitelist_status": "all_ads",
  "contest_mode": false,
  "mod_reports": [],
  "author_patreon_flair": false,
  "author_flair_text_color": null,
  "permalink": "/r/investing/comments/oyh3y7/moderna_announces_q2_results_crushes_earnings/",
  "parent_whitelist_status": "all_ads",
  "stickied": false,
  "url": "https://www.reddit.com/r/investing/comments/oyh3y7/moderna_announces_q2_results_crushes_earnings/",
  "subreddit_subscribers": 1893866,
  "created_utc": 1628178906,
  "num_crossposts": 0,
  "media": null,
  "is_video": false,
  "original_created_utc": 1628168647,
  "the_new_excerpt": "Moderna Inc. announced its Q2 results on Thursday before the bell. \n\nKey Highlights:\n\n * Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and\n   Provides Business Updates.\n * Moderna COVID-19 Vaccine mRNA-1273: Final blinded analysis of Phase 3 COVE\n   study shows 93% efficacy;…",
  "localize": [
    {
      "locale": "ja",
      "the_new_excerpt": "Moderna Inc.は、木曜日のベルの前に第2四半期の業績を発表しました。 \n\n主なハイライト\n\n * Moderna社は、2021年度第2四半期の業績報告と\n   ビジネスアップデートを提供します。\n * Moderna COVID-19 ワクチン mRNA-1273: 第3相COVE試験の最終盲検解析で93％の有効性を確認\n   試験で93％の有効性を示す；...",
      "title": "Moderna社が第2四半期の業績を発表、収益を圧迫"
    },
    {
      "locale": "zh",
      "the_new_excerpt": "Moderna Inc.周四在收盘前公布了其第二季度业绩。 \n\n主要亮点。\n\n * Moderna公布了2021财年第二季度的财务业绩，并提供了业务更新。\n   提供业务更新。\n * Moderna COVID-19疫苗mRNA-1273。3期COVE研究的最终盲法分析显示93%的疗效\n   研究的最终盲法分析显示93%的疗效；...",
      "title": "Moderna公布第二季度业绩；压低收益"
    },
    {
      "locale": "zh-Hant",
      "the_new_excerpt": "Moderna Inc.週四在收盤前公佈了其第二季度業績。 \n\n主要亮點。\n\n * Moderna公佈了2021財年第二季度的財務業績，並提供了業務更新。\n   提供業務更新。\n * Moderna COVID-19疫苗mRNA-1273。3期COVE研究的最終盲法分析顯示93%的療效\n   研究的最終盲法分析顯示93%的療效；...",
      "title": "Moderna公佈第二季度業績；壓低收益"
    }
  ],
  "source_updated_at": 1628847698275
}